These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 30679302

  • 41. Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
    Matyjaszek-Matuszek B, Lenart-Lipińska M, Rogalska D, Nowakowski A, GWAA Polish Study Group.
    Endokrynol Pol; 2013; 64(5):375-82. PubMed ID: 24186595
    [Abstract] [Full Text] [Related]

  • 42. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [Abstract] [Full Text] [Related]

  • 43. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
    Pfohl M, Siegmund T, Pscherer S, Pegelow K, Seufert J.
    Vasc Health Risk Manag; 2015 Aug; 11():569-78. PubMed ID: 26604774
    [Abstract] [Full Text] [Related]

  • 44. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
    Ridge T, Moretto T, MacConell L, Pencek R, Han J, Schulteis C, Porter L.
    Diabetes Obes Metab; 2012 Dec; 14(12):1097-103. PubMed ID: 22734440
    [Abstract] [Full Text] [Related]

  • 45. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
    Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B.
    Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
    [Abstract] [Full Text] [Related]

  • 46. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
    Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T.
    Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
    [Abstract] [Full Text] [Related]

  • 47. The GesTIO protocol experience: safety of a standardized order set for subcutaneous insulin regimen in elderly hospitalized patients.
    Franchin A, Maran A, Bruttomesso D, Corradin ML, Rossi F, Zanatta F, Barbato GM, Sicolo N, Manzato E.
    Aging Clin Exp Res; 2017 Dec; 29(6):1087-1093. PubMed ID: 28238154
    [Abstract] [Full Text] [Related]

  • 48. Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.
    Zhang J, Xian TZ, Wu MX, Li C, Pan Q, Guo LX.
    Cardiovasc Diabetol; 2020 Apr 25; 19(1):48. PubMed ID: 32334592
    [Abstract] [Full Text] [Related]

  • 49. Reliability of Inpatient CGM: Comparison to Standard of Care.
    Price C, Ditton G, Russell GB, Aloi J.
    J Diabetes Sci Technol; 2023 Mar 25; 17(2):329-335. PubMed ID: 34911384
    [Abstract] [Full Text] [Related]

  • 50. Randomized controlled trial of insulin supplementation for correction of bedtime hyperglycemia in hospitalized patients with type 2 diabetes.
    Vellanki P, Bean R, Oyedokun FA, Pasquel FJ, Smiley D, Farrokhi F, Newton C, Peng L, Umpierrez GE.
    Diabetes Care; 2015 Apr 25; 38(4):568-74. PubMed ID: 25665812
    [Abstract] [Full Text] [Related]

  • 51. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ, Scism-Bacon JL, Zagar AJ.
    Diabetes Obes Metab; 2006 Jul 25; 8(4):448-55. PubMed ID: 16776752
    [Abstract] [Full Text] [Related]

  • 52. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S, Koenen C, Bode B.
    Clin Ther; 2009 Oct 25; 31(10):2086-97. PubMed ID: 19922879
    [Abstract] [Full Text] [Related]

  • 53. Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes.
    Galindo RJ, Pasquel FJ, Vellanki P, Alicic R, Lam DW, Fayfman M, Migdal AL, Davis GM, Cardona S, Urrutia MA, Perez-Guzman C, Zamudio-Coronado KW, Peng L, Tuttle KR, Umpierrez GE.
    Diabetes Obes Metab; 2022 Jan 25; 24(1):42-49. PubMed ID: 34490700
    [Abstract] [Full Text] [Related]

  • 54. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
    Yki-Järvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, Riddle MC, EDITION 2 Study Investigators.
    Diabetes Care; 2014 Dec 25; 37(12):3235-43. PubMed ID: 25193531
    [Abstract] [Full Text] [Related]

  • 55. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.
    Roach P, Bai S, Charbonnel B, Consoli A, Taboga C, Tiengo A, Bolli G, High Mix Study Group.
    Clin Ther; 2004 Apr 25; 26(4):502-10. PubMed ID: 15189747
    [Abstract] [Full Text] [Related]

  • 56. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial).
    Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, Puig A, Mejia R.
    Diabetes Care; 2007 Sep 25; 30(9):2181-6. PubMed ID: 17513708
    [Abstract] [Full Text] [Related]

  • 57. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
    Billings LK, Doshi A, Gouet D, Oviedo A, Rodbard HW, Tentolouris N, Grøn R, Halladin N, Jodar E.
    Diabetes Care; 2018 May 25; 41(5):1009-1016. PubMed ID: 29483185
    [Abstract] [Full Text] [Related]

  • 58. Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes.
    Krzymień J, Kobli T, Nazar M.
    Pol Arch Med Wewn; 2010 Nov 25; 120(11):444-50. PubMed ID: 21102380
    [Abstract] [Full Text] [Related]

  • 59. Comparison of an Electronic Glycemic Management System Versus Provider-Managed Subcutaneous Basal Bolus Insulin Therapy in the Hospital Setting.
    Aloi J, Bode BW, Ullal J, Chidester P, McFarland RS, Bedingfield AE, Mabrey M, Booth R, Mumpower A, Wallia A.
    J Diabetes Sci Technol; 2017 Jan 25; 11(1):12-16. PubMed ID: 27555601
    [Abstract] [Full Text] [Related]

  • 60. Glycemic control in medical inpatients with type 2 diabetes mellitus receiving sliding scale insulin regimens versus routine diabetes medications: a multicenter randomized controlled trial.
    Dickerson LM, Ye X, Sack JL, Hueston WJ.
    Ann Fam Med; 2003 Jan 25; 1(1):29-35. PubMed ID: 15043177
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.